<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08997</article-id><article-id pub-id-type="doi">10.7554/eLife.08997</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Registered Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Human Biology and Medicine</subject></subj-group></article-categories><title-group><article-title>Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-34763"><name><surname>Fung</surname><given-names>Juan José</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-34764"><name><surname>Kosaka</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-34765"><name><surname>Shan</surname><given-names>Xiaochuan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-34766"><name><surname>Danet-Desnoyers</surname><given-names>Gwenn</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-34767"><name><surname>Gormally</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-29160"><name><surname>Owen</surname><given-names>Kate</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><label>1</label><institution>ProNovus Bioscience</institution>, <addr-line><named-content content-type="city">Mountain View</named-content></addr-line>, <country>California</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Stem Cell and Xenograft Core</institution>, <institution>University of Pennsylvania, Perelman School of Medicine</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>Pennsylvania</country></aff><aff id="aff3"><label>3</label><institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution>University of Virginia</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>Virginia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-5892"><name><surname>Adelman</surname><given-names>Karen</given-names></name><role>Reviewing editor</role><aff><institution>National Institute of Environmental Health Sciences</institution>, <country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Iorns</surname><given-names>Elizabeth</given-names></name><aff><institution>Science Exchange, Palo Alto</institution>, <addr-line><named-content content-type="city">California</named-content></addr-line></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Gunn</surname><given-names>William</given-names></name><aff><institution>Mendeley</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Tan</surname><given-names>Fraser</given-names></name><aff><institution>Science Exchange, Palo Alto</institution>, <addr-line><named-content content-type="city">California</named-content></addr-line></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Lomax</surname><given-names>Joelle</given-names></name><aff><institution>Science Exchange, Palo Alto</institution>, <addr-line><named-content content-type="city">California</named-content></addr-line></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Perfito</surname><given-names>Nicole</given-names></name><aff><institution>Science Exchange, Palo Alto</institution>, <addr-line><named-content content-type="city">California</named-content></addr-line></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Errington</surname><given-names>Timothy</given-names></name><aff><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>Virginia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>tim@cos.io</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>01</day><month>09</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>e08997</elocation-id><history><date date-type="received"><day>02</day><month>06</month><year>2015</year></date><date date-type="accepted"><day>04</day><month>08</month><year>2015</year></date><fn><p><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Dittmann</surname><given-names>A</given-names></name><name><surname>Giotopoulos</surname><given-names>G</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>WI</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Hopf</surname><given-names>C</given-names></name><name><surname>Savitski</surname><given-names>MM</given-names></name><name><surname>Huthmacher</surname><given-names>C</given-names></name><name><surname>Gudgin</surname><given-names>E</given-names></name><name><surname>Lugo</surname><given-names>D</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Chapman</surname><given-names>TD</given-names></name><name><surname>Roberts</surname><given-names>EJ</given-names></name><name><surname>Soden</surname><given-names>PE</given-names></name><name><surname>Auger</surname><given-names>KR</given-names></name><name><surname>Mirguet</surname><given-names>O</given-names></name><name><surname>Doehner</surname><given-names>K</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Huntly</surname><given-names>BJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group>. <year>2011</year>. <article-title>Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia</article-title>. <source>Nature</source> <volume>478</volume>:<fpage>529</fpage>–<lpage>533</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature10509</pub-id>.</mixed-citation></p></fn></history><permissions><copyright-statement>© 2015, Fung et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Fung et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-08997-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.08997.001</object-id><p>The <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/home/">Reproducibility Project: Cancer Biology</ext-link> seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/studies/">citations and Altmetric scores</ext-link> (<xref ref-type="bibr" rid="bib10">Errington et al., 2014</xref>). This Registered report describes the proposed replication plan of key experiments from ‘Inhibition of bromodomain and extra terminal (BET) recruitment to chromatin as an effective treatment for mixed-lineage leukemia (MLL)-fusion leukemia’ by Dawson and colleagues, published in <italic>Nature</italic> in 2011 (<xref ref-type="bibr" rid="bib7">Dawson et al., 2011</xref>). The experiments to be replicated are those reported in Figures 2A, 3D, 4B, 4D and Supplementary Figures 11A-B and 16A. In this study, BET proteins were demonstrated as potential therapeutic targets for modulating aberrant gene expression programs associated with MLL-fusion leukemia. In Figure 2A, the BET bromodomain inhibitor I-BET151 was reported to suppress growth of cells harboring MLL-fusions compared to those with alternate oncogenic drivers. In Figure 3D, treatment of MLL-fusion leukemia cells with I-BET151 resulted in transcriptional suppression of the anti-apoptotic gene <italic>BCL2</italic>. Figures 4B and 4D tested the therapeutic efficacy of I-BET151 in vivo using mice injected with human MLL-fusion leukemia cells and evaluated disease progression following I-BET151 treatment. The Reproducibility Project: Cancer Biology is a collaboration between the <ext-link ext-link-type="uri" xlink:href="http://centerforopenscience.org/">Center for Open Science</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.scienceexchange.com/">Science Exchange</ext-link> and the results of the replications will be published in <italic>eLife</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.08997.001">http://dx.doi.org/10.7554/eLife.08997.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>Reproducibility Project: Cancer Biology</kwd><kwd>methodology</kwd><kwd>bromodomain inhibitor</kwd><kwd>leukemia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Laura and John Arnold Foundation</institution></institution-wrap></funding-source><principal-award-recipient>Reproducibility Project: Cancer Biology</principal-award-recipient></award-group><funding-statement>The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funder had no role in study design or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.3</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The mixed-lineage leukemia (<italic>MLL</italic>) gene encodes a large histone methyltransferase that directly binds DNA and positively regulates gene transcription (<xref ref-type="bibr" rid="bib16">Marschalek, 2010</xref>). <italic>MLL</italic> is a frequent target of chromosomal translocation events (<xref ref-type="bibr" rid="bib18">Meyer et al., 2009</xref>). During rearrangement, the N-terminus of <italic>MLL</italic> fuses to one of more than 60 partners, the most common of which coexist in a super elongation complex (SEC) enriched with transcription elongation factors (<xref ref-type="bibr" rid="bib18">Meyer et al., 2009</xref>; <xref ref-type="bibr" rid="bib26">Smith et al., 2011</xref>). The resulting fusion event converts <italic>MLL</italic> into a potent transcriptional activator often giving rise to aggressive hematological malignancies (<xref ref-type="bibr" rid="bib19">Mueller et al., 2009</xref>; <xref ref-type="bibr" rid="bib25">Slany, 2009</xref>). The overall prognosis for pediatric and adult patients with confirmed MLL-fusion leukemia remains extremely poor and necessitates the development of new methodologies and therapeutic agents to improve survival outcomes (<xref ref-type="bibr" rid="bib25">Slany, 2009</xref>; <xref ref-type="bibr" rid="bib27">Tamai and Inokuchi, 2010</xref>).</p><p>Bromodomain and extra terminal (BET) proteins are transcriptional regulators that epigenetically control the expression of genes involved in cell cycle, growth and inflammation (<xref ref-type="bibr" rid="bib5">Darnell, 2002</xref>; <xref ref-type="bibr" rid="bib29">Wu and Chiang, 2007</xref>; <xref ref-type="bibr" rid="bib13">LeRoy et al., 2008</xref>; <xref ref-type="bibr" rid="bib9">Dey et al., 2009</xref>; <xref ref-type="bibr" rid="bib20">Nicodeme et al., 2010</xref>). BETs therefore provide potential therapeutic targets for modulating gene expression programs associated with various human diseases. Dawson and colleagues identified novel interactions between BET family members bromodomain protein (BRD) 3 and BRD4 with components of the SEC and polymerase-associated factor complexes in MLL fusion cells (<xref ref-type="bibr" rid="bib7">Dawson et al., 2011</xref>). Given that BRD3 and BRD4 may be involved in the recruitment of the SEC and PAF complexes to regions of active chromatin, the authors tested the hypothesis that the dislocation of BET proteins from chromatin constitutes a viable therapeutic strategy in the treatment of MLL-fusion leukemia. For this purpose, Dawson and colleagues developed I-BET151, a BET inhibitor that selectively binds to the bromodomains of BET proteins and prevents their ability to bind acetylated histone residues (<xref ref-type="bibr" rid="bib7">Dawson et al., 2011</xref>).</p><p>In Figure 2A and S11A-B, Dawson and colleagues assessed the ability of I-BET151 to suppress cell growth in a variety of human leukemia cell lines (<xref ref-type="bibr" rid="bib7">Dawson et al., 2011</xref>). In these experiments, cells were treated with increasing concentrations of I-BET151 and allowed to grow for a further 72 hr. I-BET151 treatment was extremely effective at inhibiting the growth of leukemic cell lines harboring MLL fusions, including MV4;11, RS4;11, MOLM13, and NOMO1 cells, as determined by their low (nanomolar range) IC<sub>50</sub> values. In contrast, the proliferation of cell lines using other oncogenic drivers, including gain-of-function kinase activity, was either resistant (K526) or significantly less sensitive (human erythroleukemic [HEL], HL60, and MEG01 cells) to I-BET151, exhibiting IC<sub>50</sub> concentrations in the micromolar range and above. This key experiment shows that I-BET151 exhibits potent efficacy against MLL-fusion leukemic cell lines and will be replicated in Protocol 2. More recently, substantial growth inhibition with I-BET151 has been observed in other hematological malignancies, including acute myeloid leukemia (AML) (<xref ref-type="bibr" rid="bib6">Dawson et al., 2014</xref>), multiple myeloma (MM) (<xref ref-type="bibr" rid="bib1">Chaidos et al., 2014</xref>), and primary effusion lymphoma (<xref ref-type="bibr" rid="bib28">Tolani et al., 2014</xref>), as well as non-hematological cancer models (medulloblastoma, melanoma, and glioblastoma) at concentrations ranging from 100 to 500 nM (<xref ref-type="bibr" rid="bib12">Gallagher et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Long et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Pastori et al., 2014</xref>). Additionally, the BET inhibitor JQ1 was reported to have a broad growth-suppressive activity, similar to I-BET151, effectively inhibiting leukemic cell lines, such as MV4;11, while K526 cells remained largely resistant (<xref ref-type="bibr" rid="bib31">Zuber et al., 2011</xref>).</p><p>To investigate the mechanism of action for I-BET151, Dawson and colleagues assessed apoptosis and cell cycle progression after drug treatment. Closer examination of the transcriptional pathways controlled by I-BET151 revealed that drug treatment repressed the activity of several known <italic>MLL</italic> targets, including the oncogene <italic>BCL-2</italic>. Bcl-2 promotes cell survival and protects cells from a wide range of cytotoxic insults (<xref ref-type="bibr" rid="bib4">Cory et al., 2003</xref>). In Figure 3D, the authors confirmed the ability of I-BET151 to transcriptionally downregulate <italic>BCL-2</italic> expression in the MLL-fusion cell lines MOLM13, MV4;11, and NOMO1, but not in the K526 resistant cell line. This key experiment shows that I-BET151 is effective at silencing <italic>BCL-2</italic> gene transcription and will be replicated in Protocol 3. In addition to MLL-fusion cell lines, I-BET151 treatment correlated with enhanced apoptosis and reduced <italic>BCL-2</italic> gene transcription in AML patient samples (<xref ref-type="bibr" rid="bib6">Dawson et al., 2014</xref>). In contrast, while I-BET151 also promoted cell death and/or growth inhibition in HEL cells (<xref ref-type="bibr" rid="bib30">Wyspianska et al., 2014</xref>), Me1007 melanoma cells (<xref ref-type="bibr" rid="bib12">Gallagher et al., 2014</xref>), and Sufu<sup>−/−</sup> cells (mouse embryo fibroblasts deficient in the hedge hog signaling molecule Smoothened) (<xref ref-type="bibr" rid="bib14">Long et al., 2014</xref>), drug treatment did not significantly impact Bcl-2 at either the gene or protein expression level.</p><p>In Figure 4B and 4D (and Supp. Figure 16A), the therapeutic potential of I-BET151 treatment was tested in vivo. Using a well-established model of disseminated MLL leukemia, animals were treated with I-BET151 21 days after transplantation with MV4;11 cells and monitored for clinical signs of disease. Here, Dawson and colleagues showed that I-BET151 significantly improved the length of disease-free survival and reduced evidence of peripheral blood (PB) disease compared to vehicle-treated animals. Similar findings recapitulating the suppressive effect of I-BET151 on tumor growth have been reported in medulloblastoma, melanoma, and glioblastoma xenograft models (<xref ref-type="bibr" rid="bib12">Gallagher et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Long et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Pastori et al., 2014</xref>). Similarly, follow-up studies by Dawson and colleagues demonstrated that I-BET151 confers a significant survival advantage and reduces the circulating leukemic burden in a murine model of AML (<xref ref-type="bibr" rid="bib6">Dawson et al., 2014</xref>). These experiments will be replicated in Protocols 4 and 5. Similar studies testing the efficacy of JQ1, an independent BET inhibitor, reported a decrease in tumor growth in nude mice bearing AML xenografts (MV4;11 cells) (<xref ref-type="bibr" rid="bib17">Mertz et al., 2011</xref>) and SCID-beige mice bearing MM xenografts (MM.1S cells) (<xref ref-type="bibr" rid="bib8">Delmore et al., 2011</xref>).</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Protocol 1: Determine the population doubling time of K562 and MV4;11 cells</title><p>The doubling time of K-562 and MV4;11 cells is assumed to be approximately 25 and 50 hr, respectively. To empirically determine the doubling time in the replicating lab, this general protocol will be used to determine the treatment time of K562 and MV4;11 cells for Protocol 2.</p><sec id="s2-1-1"><title>Sampling</title><p><list list-type="simple"><list-item><p>■ This experiment is performed with two cell lines (K562 and MV4;11).</p></list-item><list-item><p>■ Each cell line to be performed with six technical repeats per experiment.</p></list-item><list-item><p>■ The experiment is performed a total of once.</p></list-item></list></p></sec><sec id="s2-1-2"><title>Materials and reagents</title><p><table-wrap id="tblu1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>MV4;11</td><td>Human cell line</td><td>ATCC</td><td>CRL-9591</td><td>–</td></tr><tr><td>K-562</td><td>Human cell line</td><td>ATCC</td><td>CCL-243</td><td>–</td></tr><tr><td>RPMI-1640 medium, with L-glutamine and sodium bicarbonate</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>R8758</td><td>Original catalog number not specified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>F2442</td><td>Original brand not specified</td></tr><tr><td>Penicillin–streptomycin solution (100×) stabilized</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>P4333</td><td>Original brand not specified</td></tr><tr><td>T-75 flasks</td><td>Labware</td><td>Corning</td><td>430641U</td><td>Original brand not specified</td></tr><tr><td>96-well tissue culture plates (optically clear)</td><td>Labware</td><td>Corning</td><td>3595</td><td>Original brand not specified</td></tr><tr><td>Cell-titer aqueous one solution cell proliferation assay (MTS)</td><td>Assay kit</td><td>Promega</td><td>G3582</td><td>–</td></tr><tr><td>Plate reader capable of reading absorbance at 490 nm</td><td>Instrument</td><td>Molecular Devices</td><td>SpectraMax 190</td><td>Replaces Gemini reader</td></tr><tr><td>Softmax Pro</td><td>Software</td><td>Molecular Devices</td><td>Version 3.1.2</td><td>–</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-1-3"><title>Procedure</title><sec id="s2-1-3-1"><title>Note</title><p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item><list-item><p>MV4;11 and K-562 human leukemic cells are maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C with 5% CO<sub>2</sub>.</p></list-item></list><list list-type="order"><list-item><p>Seed between 4 × 10<sup>4</sup> and 1 × 10<sup>5</sup> cells into two 96-well tissue culture plates with 100 µl of medium per well, excluding outer wells. Incubate cells overnight at 37°C with 5% CO<sub>2</sub>.</p><list list-type="simple"><list-item><p>a. Fill outer wells with medium alone.</p></list-item><list-item><p>b. Include six non-outer wells with medium alone for background subtraction.</p></list-item></list></list-item><list-item><p>With one plate perform MTS Assay (Promega CellTiter-Aqueous One) according to manufacturer's instructions.</p><list list-type="simple"><list-item><p>a. Incubate plates for 4 hr at 37°C.</p></list-item><list-item><p>b. Read absorbance at 490 nm.</p></list-item><list-item><p>c. Subtract background (average of medium only wells) from wells with cells and determine average reading from first plate.</p></list-item></list></list-item><list-item><p>3 days later perform MTS Assay (Promega CellTiter-Aqueous One) according to manufacturer's instructions on second plate.</p><list list-type="simple"><list-item><p>a. Incubate plates for 4 hr at 37°C.</p></list-item><list-item><p>b. Read absorbance at 490 nm.</p></list-item><list-item><p>c. Subtract background (average of medium only wells) from wells with cells and determine average reading from second plate.</p></list-item></list></list-item><list-item><p>Calculate the population doubling time for each cell line using the following formula:</p><list list-type="simple"><list-item><p>a. Doubling time = ln2/ln(second plate average reading/first plate average reading).</p></list-item></list></list-item></list></p></sec></sec><sec id="s2-1-4"><title>Deliverables</title><p><list list-type="simple"><list-item><p>■ Data to be collected:</p><list list-type="simple"><list-item><p>○ STR profile and result of mycoplasma testing.</p></list-item><list-item><p>○ Raw data and background subtracted absorbance at 490 nm.</p></list-item></list></list-item></list></p></sec><sec id="s2-1-5"><title>Confirmatory analysis plan</title><p><list list-type="simple"><list-item><p>■ n/a.</p></list-item></list></p></sec><sec id="s2-1-6"><title>Known differences from the original study</title><p>All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-1-7"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/hcqqy">https://osf.io/hcqqy</ext-link>) and made publically available.</p></sec></sec><sec id="s2-2"><title>Protocol 2: Cell viability assay to determine selective inhibition of an MLL-fusion leukemic cell line with I-BET151</title><p>This protocol assesses the ability of I-BET151, a small molecule inhibitor of BET family proteins, to selectively and potently inhibit the growth of the human leukemic cell line MV4;11, which is driven by an oncogenic translocation of the <italic>MLL</italic> gene. As a negative control, human K-562 leukemic cells, which are not oncogenically driven by an MLL-fusion, will also be treated with I-BET151. As a further negative control, both cell lines will be treated with vehicle alone (dimethyl sulfoxide (DMSO)). This protocol will replicate experiments reported in Figure 2A, Supp. Figure 11A, and Supp. Figure 11B.</p><sec id="s2-2-1"><title>Sampling</title><p><list list-type="simple"><list-item><p>■ This experiment will be performed three separate times (biological replicates) for a final power of ≥80%. The original data reported a single IC<sub>50</sub> value for each cell line, thus to determine an appropriate number of replicates to perform initially, sample sizes required based on a range of potential variance was determined. The sample size will also be determined <italic>post hoc</italic> as described in ‘Power calculations’ and additional replicates will be performed if necessary.</p><list list-type="simple"><list-item><p>○ See ‘Power calculations’ section for details.</p></list-item></list></list-item><list-item><p>■ Experiment has two cohorts:</p><list list-type="simple"><list-item><p>○ K562 human leukemic cells (−MLL).</p></list-item><list-item><p>○ MV4;11 human leukemic cells (+MLL).</p></list-item></list></list-item><list-item><p>■ Each cohort has 11 conditions to be performed in technical triplicate per experiment:</p><list list-type="simple"><list-item><p>○ DMSO (vehicle).</p></list-item><list-item><p>○ 0.01 nM I-BET151.</p></list-item><list-item><p>○ 0.1 nM I-BET151.</p></list-item><list-item><p>○ 1 nM I-BET151.</p></list-item><list-item><p>○ 10 nM I-BET151.</p></list-item><list-item><p>○ 100 nM I-BET151.</p></list-item><list-item><p>○ 1 µM I-BET151.</p></list-item><list-item><p>○ 10 µM I-BET151.</p></list-item><list-item><p>○ 100 µM I-BET151.</p></list-item><list-item><p>○ 1 mM I-BET151.</p></list-item><list-item><p>○ 10 mM I-BET151.</p></list-item></list></list-item></list></p></sec><sec id="s2-2-2"><title>Materials and reagents</title><p><table-wrap id="tblu2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>MV4;11</td><td>Human cell line</td><td>ATCC</td><td>CRL-9591</td><td>–</td></tr><tr><td>K-562</td><td>Human cell line</td><td>ATCC</td><td>CCL-243</td><td>–</td></tr><tr><td>I-BET151 (GSK1210151A)</td><td>Small molecule</td><td>Sigma–Aldrich</td><td>SML0666</td><td>–</td></tr><tr><td>RPMI-1640 medium, with L-glutamine and sodium bicarbonate</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>R8758</td><td>Original catalog number not specified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>F2442</td><td>Original brand not specified</td></tr><tr><td>Penicillin–streptomycin solution (100×) stabilized</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>P4333</td><td>Original brand not specified</td></tr><tr><td>T-75 flasks</td><td>Labware</td><td>Corning</td><td>430641U</td><td>Original brand not specified</td></tr><tr><td>96-well tissue culture plates (optically clear)</td><td>Labware</td><td>Corning</td><td>3595</td><td>Original brand not specified</td></tr><tr><td>96-well sterile plate (for preparing compound dilutions)</td><td>Labware</td><td>Corning</td><td>3370</td><td>Original brand not specified</td></tr><tr><td>DMSO, molecular biology grade</td><td>Reagent</td><td>Sigma–Aldrich</td><td>D8418</td><td>Original brand not specified</td></tr><tr><td>Cell-titer aqueous one solution cell proliferation assay (MTS)</td><td>Assay kit</td><td>Promega</td><td>G3582</td><td>–</td></tr><tr><td>Plate reader capable of reading absorbance at 490 nm</td><td>Instrument</td><td>Molecular Devices</td><td>SpectraMax 190</td><td>Replaces Gemini reader</td></tr><tr><td>Softmax Pro</td><td>Software</td><td>Molecular Devices</td><td>Version 3.1.2</td><td>–</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-2-3"><title>Procedure</title><sec id="s2-2-3-1"><title>Note</title><p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item><list-item><p>MV4;11 and K-562 human leukemic cells maintained in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C with 5% CO<sub>2</sub>.</p></list-item></list><list list-type="order"><list-item><p>Seed between 4 × 10<sup>4</sup> and 1 × 10<sup>5</sup> cells into 96-well tissue culture plates with 90 µl of medium per well, excluding outer wells. Incubate cells overnight at 37°C with 5% CO<sub>2</sub>.</p><list list-type="simple"><list-item><p>a. Fill outer wells with medium alone.</p></list-item><list-item><p>b. Include at least three non-outer wells with medium alone for background subtraction.</p></list-item><list-item><p>c. One plate for each cell line with 33 wells seeded with cells for each plate.</p></list-item></list></list-item><list-item><p>Treat cells with 10 µl of 10× serial dilutions of I-BET151 to yield final dilutions of 0.01 nM–10 mM (10 dilutions), or treat with DMSO (vehicle) control.</p><list list-type="simple"><list-item><p>a. Dilute stock of I-BET151 at 1000× final concentration of serial dilution stocks in DMSO (10 nM–10 M).</p></list-item><list-item><p>b. Dilute 1000× serial dilution stocks 1:100 in complete growth medium to yield a 10× stock (0.1 nM–100 mM) that is added directly to the 90 µl of cell/medium.</p><list list-type="simple"><list-item><p>i. Final DMSO concentration kept to 0.1% DMSO.</p></list-item></list></list-item></list></list-item><list-item><p>Incubate cells for approximately three times the doubling time of each cell line.</p><list list-type="simple"><list-item><p>a. The doubling time for each cell line is determined in Protocol 1.</p></list-item></list></list-item><list-item><p>Perform MTS Assay (Promega CellTiter-Aqueous One<sup>®</sup>) according to manufacturer's instructions.</p><list list-type="simple"><list-item><p>a. Incubate plates for 4 hr at 37°C.</p></list-item><list-item><p>b. Read absorbance at 490 nm.</p></list-item><list-item><p>c. Calculate viability as a percentage of control (DMSO (vehicle) cells) after background subtraction.</p></list-item></list></list-item><list-item><p>Determine IC50 values for each cell line.</p></list-item><list-item><p>Repeat independently two additional times.</p></list-item></list></p></sec></sec><sec id="s2-2-4"><title>Deliverables</title><p><list list-type="bullet"><list-item><p>Data to be collected:</p><list list-type="simple"><list-item><p>○ STR profile and result of mycoplasma testing of cells.</p></list-item><list-item><p>○ Raw absorbance data, I-BET151 values at each concentration normalized to DMSO-treated control values, and analyzed data (sigmoidal dose–response curves for I-BET151), and IC<sub>50</sub> values determined for each cell line and repeat. (Compare to Figures S11A and S11B).</p></list-item></list></list-item></list></p></sec><sec id="s2-2-5"><title>Confirmatory analysis plan</title><p><list list-type="bullet"><list-item><p>Statistical analysis of the replication data:</p><list list-type="simple"><list-item><p>○ Unpaired two-tailed <italic>t</italic>-test of the IC<sub>50</sub> values for I-BET151 treated K-562 cells will be compared to IC<sub>50</sub> values for I-BET151 treated MV4;11 cells.</p></list-item></list></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:</p><list list-type="simple"><list-item><p>○ The replication data (mean and 95% confidence interval) will be plotted with the original reported data value displayed as a single point on the same plot for comparison.</p></list-item></list></list-item></list></p></sec><sec id="s2-2-6"><title>Known differences from the original study</title><p>All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-2-7"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. The doubling time of each cell line was determined in Protocol 1. All of the raw data will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/hcqqy">https://osf.io/hcqqy</ext-link>) and made publically available.</p></sec></sec><sec id="s2-3"><title>Protocol 3: qPCR analysis of <italic>BCL2</italic> gene expression following I-BET151 treatment</title><p>This protocol evaluates the expression of the <italic>BCL2</italic> gene in both MV4;11 (+MLL) and K-562 (−MLL) leukemic cell lines following treatment with the BET inhibitor I-BET151. <italic>BCL2</italic> is a key anti-apoptotic gene implicated in the pathogenesis of MLL-fusion leukemias. Treatment with I-BET151 is expected to reduce the expression of <italic>BCL2</italic> in MV4;11 cells, but not in the unresponsive K-562 cells. As a control, both cell lines will also be treated with vehicle alone (DMSO only). The expression of <italic>BCL2</italic> will be normalized against the endogenous expression of β<sub>2</sub> microglobulin (<italic>B2M</italic>). This protocol will replicate experiments reported in Figure 3D.</p><sec id="s2-3-1"><title>Sampling</title><p><list list-type="simple"><list-item><p>■ Perform this experiment three separate times (biological replicates) for a minimum power of 80%.</p><list list-type="simple"><list-item><p>○ See ‘Power calculations’ section for details.</p></list-item></list></list-item><list-item><p>■ Experiment has two cohorts:</p><list list-type="simple"><list-item><p>○ K562 human leukemic cells (−MLL).</p></list-item><list-item><p>○ MV4;11 human leukemic cells (+MLL).</p></list-item></list></list-item><list-item><p>■ Each cohort has two conditions to be performed in technical duplicate per experiment (qRT-PCR of <italic>BCL2</italic> and <italic>B2M</italic>):</p><list list-type="simple"><list-item><p>○ DMSO (vehicle).</p></list-item><list-item><p>○ 500 nM I-BET151.</p></list-item></list></list-item></list></p></sec><sec id="s2-3-2"><title>Materials and reagents</title><p><table-wrap id="tblu3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>MV4;11</td><td>Human cell line</td><td>ATCC</td><td>CRL-9591</td><td>–</td></tr><tr><td>K-562</td><td>Human cell line</td><td>ATCC</td><td>CCL-243</td><td>–</td></tr><tr><td>I-BET151 (GSK1210151A)</td><td>Small molecule</td><td>Sigma–Aldrich</td><td>SML0666</td><td>–</td></tr><tr><td>DMSO, molecular biology grade</td><td>Reagent</td><td>Sigma–Aldrich</td><td>D8418</td><td>Original brand not specified</td></tr><tr><td>RPMI-1640 medium, with L-glutamine and sodium bicarbonate</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>R8758</td><td>Original catalog number not specified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>F2442</td><td>Original brand not specified</td></tr><tr><td>Penicillin–streptomycin solution (100×) stabilized</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>P4333</td><td>Original brand not specified</td></tr><tr><td>48-well tissue culture plates</td><td>Labware</td><td>Corning</td><td>3548</td><td>Original brand not specified</td></tr><tr><td>RNAspin mini</td><td>RNA isolation</td><td>Sigma–Aldrich</td><td>GE25-0500-70</td><td>Replaces Qiagen cat. no. 74104 used in original study</td></tr><tr><td>Nuclease-free water (DEPC-treated)</td><td>Chemical</td><td>Sigma–Aldrich</td><td>95284</td><td>Reagent needed for RNAspin Mini protocol</td></tr><tr><td>96-well plates (for quantification of RNA)</td><td>Labware</td><td>Corning</td><td>3635</td><td>UV/Vis 96-well clear plates for use on Molecular Devices Spectramax 190</td></tr><tr><td>First-strand cDNA synthesis kit</td><td>cDNA synthesis</td><td>Sigma–Aldrich</td><td>GE27-9261-01</td><td>Replaces Invitrogen cat. no. 28025-013 used in original study</td></tr><tr><td><italic>BCL2</italic>-primers (forward and reverse)</td><td>Nucleic acid</td><td colspan="3" rowspan="2">Sequences listed below in procedure; specific brand information will be left up to the discretion of the replicating lab and recorded later</td></tr><tr><td><italic>B2M</italic>-primers (forward and reverse)</td><td>Nucleic acid</td></tr><tr><td>96-well multiplate PCR plates, clear</td><td>qPCR</td><td>Bio-Rad</td><td>MLL9601</td><td>Original brand not specified</td></tr><tr><td>qPCR plate seals</td><td>Labware</td><td>Bio-Rad</td><td>MSB1001</td><td>Or equivalent optically clear seals will be used</td></tr><tr><td>SYBR<sup>®</sup> green PCR master mix</td><td>qPCR</td><td>Life Technologies</td><td>4344463</td><td>–</td></tr><tr><td>DNA engine opticon system (qRT-PCR)</td><td>Instrument</td><td>Bio-Rad</td><td>n/a</td><td>Replaces ABI 7900</td></tr><tr><td>Opticon monitor</td><td>Software</td><td>Bio-Rad</td><td>n/a</td><td>–</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-3-3"><title>Procedure</title><sec id="s2-3-3-1"><title>Note</title><p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item><list-item><p>MV4;11 and K-562 human leukemic cells maintained in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C with 5% CO<sub>2</sub>.</p></list-item></list><list list-type="order"><list-item><p>Seed MV4;11 or K-562 cells into 48-well tissue culture plates at 8 × 10<sup>4</sup> to 2 × 10<sup>5</sup> cells per well in triplicate. Incubate cells overnight at 37°C with 5% CO<sub>2</sub>.</p></list-item><list-item><p>Treat cells with DMSO or 500 nM I-BET151 for 6 hr, in triplicate.</p><list list-type="simple"><list-item><p>a. Add drug directly to each well.</p></list-item><list-item><p>b. Make stocks of I-BET151 at 1000× stock (500 µM) in DMSO.</p></list-item><list-item><p>c. Final DMSO concentration kept to 0.1%.</p></list-item></list></list-item><list-item><p>Harvest cells and isolate RNA using the RNAspin mini kit according to manufacturer's instructions.</p><list list-type="simple"><list-item><p>a. Determine RNA purity (A<sub>260/280</sub> and A<sub>260/230</sub> ratios) and concentration.</p></list-item></list></list-item><list-item><p>Prepare cDNA using SuperScript III First-Strand Synthesis System according to the manufacturer's instructions.</p></list-item><list-item><p>Perform semi-quantitative PCR reactions, in triplicate, using <italic>BCL2</italic>-specific primers, <italic>B2M</italic>-specific primers (for normalization), and SYBR green PCR mastermix according to the manufacturer's instructions.</p><list list-type="simple"><list-item><p>a. Primers:</p><list list-type="simple"><list-item><p>i. <italic>BCL2</italic> forward: AGTACCTGAACCGGCACCT.</p></list-item><list-item><p>ii. <italic>BCL2</italic> reverse: CAGCCAGGAGAAATCAAACAG.</p></list-item><list-item><p>iii. <italic>B2M</italic> forward: TGACTTTGTCACAGCCCAAG.</p></list-item><list-item><p>iv. <italic>B2M</italic> reverse: AGCAAGCAAGCAGAATTTGG.</p></list-item></list></list-item></list></list-item><list-item><p>Analyze data using the ΔΔC<sub>T</sub> method: First, normalize <italic>BCL2</italic> values to <italic>B2M</italic> (housekeeping) values. Next, normalize I-BET151-treated cells to DMSO-treated cells to determine fold change of treatment relative to DMSO.</p></list-item><list-item><p>Repeat independently two additional times.</p></list-item></list></p></sec></sec><sec id="s2-3-4"><title>Deliverables</title><p><list list-type="bullet"><list-item><p>Data to be collected:</p><list list-type="simple"><list-item><p>○ STR profile and result of mycoplasma testing of cells.</p></list-item><list-item><p>○ Purity (A<sub>260/280</sub> and A<sub>260/230</sub> ratios) and concentration of isolated total RNA from cells.</p></list-item><list-item><p>○ Raw qRT-PCR values, as well as analyzed ΔΔC<sub>T</sub> values and bar graph of <italic>BCL2</italic> mRNA normalized to control mRNA levels for each condition. (Compare to Figure 3D).</p></list-item></list></list-item></list></p></sec><sec id="s2-3-5"><title>Confirmatory analysis plan</title><p><list list-type="bullet"><list-item><p>Statistical analysis of the replication data:</p><list list-type="simple"><list-item><p>○ Two-tailed <italic>t</italic>-tests with the Bonferroni correction:</p><list list-type="simple"><list-item><p>■ Unpaired two-sample <italic>t</italic>-test of ΔΔC<sub>T</sub> values from K562 cells compared to MV4;11 cells.</p></list-item><list-item><p>■ One-sample <italic>t</italic>-test of ΔΔC<sub>T</sub> values from K562 cells compared to a constant of 1.</p></list-item><list-item><p>■ One-sample <italic>t</italic>-test of ΔΔC<sub>T</sub> values from MV4;11 cells compared to a constant of 1.</p></list-item></list></list-item></list></list-item><list-item><p>Meta-analysis of effect sizes:</p><list list-type="simple"><list-item><p>○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></list-item></list></p></sec><sec id="s2-3-6"><title>Known differences from the original study</title><p>All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-3-7"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. All of the raw data will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/hcqqy">https://osf.io/hcqqy</ext-link>) and made publically available.</p></sec></sec><sec id="s2-4"><title>Protocol 4: Assessment of maximum tolerable dose of I-BET151 in xenograft AML mouse model</title><p>This protocol assesses the maximum tolerable dose (MTD) of I-BET151 in a xenograft mouse model of leukemia by intra-peritoneal injection, using a range of I-BET151 compound. The original study reported using 30 mg/kg/day, however, as batch-to-batch variation occurs, the MTD will be assessed in this protocol to avoid toxicity. The MTD determined in this protocol will be used in Protocol 5 to assess the efficiency of I-BET151 in this model.</p><sec id="s2-4-1"><title>Sampling</title><p><list list-type="simple"><list-item><p>■ Experiment has four cohorts:</p><list list-type="simple"><list-item><p>○ Cohort 1: NOD/SCID mice treated daily with vehicle only.</p></list-item><list-item><p>○ Cohort 2: NOD/SCID mice treated daily with 10 mg/kg/day I-BET151.</p></list-item><list-item><p>○ Cohort 3: NOD/SCID mice treated daily with 20 mg/kg/day I-BET151.</p></list-item><list-item><p>○ Cohort 4: NOD/SCID mice treated daily with 30 mg/kg/day I-BET151.</p></list-item></list></list-item><list-item><p>■ Experiment will use five mice per treatment group.</p><list list-type="simple"><list-item><p>○ See ‘Power calculations’ section for details.</p></list-item></list></list-item></list></p></sec><sec id="s2-4-2"><title>Materials and reagents</title><p><table-wrap id="tblu4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>MV4;11</td><td>Human cell line</td><td>ATCC</td><td>CRL-9591</td><td>–</td></tr><tr><td>I-BET151 (GSK1210151A)</td><td>Small molecule</td><td>Sigma–Aldrich</td><td>SML0666</td><td>–</td></tr><tr><td>DMSO, molecular biology grade</td><td>Reagent</td><td>Sigma–Aldrich</td><td>D1435</td><td>Original brand not specified</td></tr><tr><td>RPMI-1640 medium, with L-glutamine and sodium bicarbonate</td><td>Cell culture reagent</td><td>Gibco, Life Technologies</td><td>22400-089</td><td>Original catalog number not specified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>F2442</td><td>Original brand not specified</td></tr><tr><td>Penicillin–streptomycin solution (100×) stabilized</td><td>Cell culture reagent</td><td>Invitrogen</td><td>15140122</td><td>Original brand not specified</td></tr><tr><td>Phosphate buffered saline (PBS)</td><td>Buffer</td><td>Gibco, Life Technologies</td><td>14190-136</td><td>–</td></tr><tr><td>Female and male NOD-SCID mice (6–8 weeks old)</td><td>Animal model</td><td>Jackson Laboratory</td><td>001303</td><td>–</td></tr><tr><td>IV Busulfex (busulfan)</td><td>Chemical</td><td>Otsuka America Pharmaceutical, Inc.</td><td>NDC 59148-070-90</td><td>Not originally used</td></tr><tr><td>½ cc LO-DOSE U-100 insulin syringe 28G</td><td>Labware</td><td>Becton–Dickinson</td><td>329461</td><td>Original brand not specified</td></tr><tr><td>APC anti-human HLA-A,B,C antibody</td><td>Antibodies</td><td>Biolegend</td><td>311410</td><td>Original catalog number not specified</td></tr><tr><td>APC mouse IgG2a, κisotype control antibody</td><td>Antibodies</td><td>Biolegend</td><td>400220</td><td>–</td></tr><tr><td>Kleptose HPB</td><td>Chemical</td><td>Roquette Pharma</td><td>n/a</td><td>Original brand not specified</td></tr><tr><td>0.9% NaCl, USP</td><td>Chemical</td><td>Hospira, Inc</td><td>0490-1966-05</td><td>Original brand not specified</td></tr><tr><td>1cc insulin syringe U-100 27G 5/8</td><td>Labware</td><td>Becton–Dickinson</td><td>329412</td><td>Original brand not specified</td></tr><tr><td>Flow cytometer</td><td>Instrument</td><td>Becton–Dickinson</td><td>n/a</td><td>Canto or LSR II (replaces CyAn ADP from Dako)</td></tr><tr><td>FlowJo software</td><td>Software</td><td>Tree Star, Inc</td><td>n/a</td><td>–</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-4-3"><title>Procedure</title><sec id="s2-4-3-1"><title>Note</title><p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling, as well as screened against a Rodent Pathogen Panel.</p></list-item><list-item><p>MV4;11 human leukemic cells maintained in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C with 5% CO<sub>2</sub>.</p></list-item></list><list list-type="order"><list-item><p>Receive non-obese diabetic/severely compromised immunodeficient (NOD-SCID) female and male mice (6–8 weeks old).</p><list list-type="simple"><list-item><p>a. An equal number of male and female mice should be used.</p></list-item><list-item><p>b. Allow animals 1 week to acclimatize in a pathogen-free enclosure before start of study.</p></list-item><list-item><p>c. Animals are housed in sterile conditions using high-efficiency particulate arrestance (HEPA)-filtered micro-isolator with 12-hr light/dark cycles, and fed with sterile rodent chow and acidified water ad libitum.</p></list-item></list></list-item><list-item><p>Condition mice with 30 mg/kg busulfan by intraperitoneal injection 24 hr prior to injection of MV4;11 cells.</p></list-item><list-item><p>Intravenously inject 1 × 10<sup>7</sup> MV4;11 cells in 0.2 ml sterile vehicle (PBS) into the tail vein of conditioned mice.</p></list-item><list-item><p>Monitor mice for engraftment:</p><list list-type="simple"><list-item><p>a. Inspect mice daily for signs of distress and record the scores using the ‘Mouse Health Scoring System’ (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1</xref>) for 21 days (<xref ref-type="bibr" rid="bib3">Cooke et al., 1996</xref>).</p></list-item><list-item><p>b. Weigh mice weekly for the entire duration of the experiment.</p></list-item><list-item><p>c. At day 21 post-injection, collect retro-orbital bleeds and analyze leukemia burden (percent human HLA-A,B,C<sup>+</sup> cells) by flow cytometry.</p><list list-type="simple"><list-item><p>i. Stain samples with the following antibodies following manufacturer's recommendations:</p><list list-type="simple"><list-item><p>1. APC conjugated anti-human HLA-A,B,C.</p></list-item><list-item><p>2. APC conjugated isotype control.</p></list-item></list></list-item><list-item><p>ii. Perform flow cytometric analysis following manufacturer's instructions.</p></list-item><list-item><p>iii. Gating strategy:</p><list list-type="simple"><list-item><p>1. On SSC vs FSC plot, gate on total nucleated population (both mouse and human cells).</p></list-item><list-item><p>2. From the nucleated population, gate on HLA-A,B,C<sup>+</sup> cells (human leukemia cells).</p></list-item></list></list-item></list></list-item></list></list-item><list-item><p>Randomize mice into four cohorts using the following method:</p><list list-type="simple"><list-item><p>a. Exclude mice with no detectable leukemia burden.</p><list list-type="simple"><list-item><p>i. Use 0.5% human leukemia cells (HLA-A,B,C<sup>+</sup> cells) over the total live nucleated cells (human and mouse cells) in sample as a minimum threshold of engraftment (leukemia detected).</p></list-item></list></list-item><list-item><p>b. Animals are randomized according to a stratified randomization procedure to balance gender and baseline tumor characteristics.</p><list list-type="simple"><list-item><p>i. Female and male mice are assigned into separate blocks.</p></list-item><list-item><p>ii. In each block, animals are ranked according to disease burden (percent human HLA-A,B,C<sup>+</sup> cells) and group assignment is performed with a simple randomization procedure.</p></list-item></list></list-item></list></list-item><list-item><p>Begin once daily intraperitoneal injections with vehicle control, 10 mg/kg I-BET151, 20 mg/kg I-BET151, or 30 mg/kg I-BET151 (dose volume is 10 ml/kg).</p><list list-type="simple"><list-item><p>a. Prepare drug delivery vehicle: (10%) wt/vol, Kleptose HPB in 0.9%/g NaCl injection solution, pH 5.0.</p><list list-type="simple"><list-item><p>i. Weigh required amount of Kleptose HPB into a suitable glass container, for example, volumetric flask.</p></list-item><list-item><p>ii. Make up to a final volume with 0.9%/g saline to achieve a 10% wt/vol, Kleptose HPB solution.</p></list-item><list-item><p>iii. Mix contents until vehicle has visually clarified.</p></list-item></list></list-item><list-item><p>b. Prepare initial formulation of I-BET151: 60 mg/ml of I-BET151 in DMSO (stock).</p><list list-type="simple"><list-item><p>i. Dispense the DMSO into the compounding vessel containing I-BET151.</p></list-item><list-item><p>ii. Gently mix for minimum of 2 min or until complete dissolution achieved.</p></list-item></list></list-item><list-item><p>c. Prepare the final drug formulation composition: 1, 2, or 3 mg/ml of I-BET151 in 5:95 vol/vol DMSO: drug delivery vehicle.</p><list list-type="simple"><list-item><p>i. Make a 20-fold dilution of the I-BET151 stock with the drug delivery vehicle; adjust pH to 5.0 using 2 M HCl to obtain a 3 mg/ml I-BET151 injection solution.</p><list list-type="simple"><list-item><p>1. Dispense the DMSO stock into a glass recipient vessel containing 25 ml of the required volume of vehicle.</p></list-item><list-item><p>2. With the remaining 4.925 ml of vehicle, rinse the vessel containing the DMSO stock, adding the rinsed volume to the compounding vessel from step 1, removing any remaining dose by pipette.</p></list-item><list-item><p>3. Gently mix for minimum of 1 min. A cloudy dose should form.</p></list-item><list-item><p>4. Accurately add 2 μl of 2 M HCl to the compounding vessel by use of pipette.</p></list-item><list-item><p>5. Gently mix for minimum of 1 min.</p></list-item><list-item><p>6. Repeat steps 4 and 5 as required until a clear solution is formed.</p></list-item><list-item><p>7. Take pH of resultant solution (final pH should be 5.0).</p></list-item></list></list-item><list-item><p>ii. Make a 1.5-fold dilution of the 3 mg/ml I-BET151 injection solution with the drug delivery vehicle to obtain a 2 mg/ml I-BET151 injection solution.</p></list-item><list-item><p>iii. Make a two-fold dilution of the 3 mg/ml I-BET151 injection solution with the drug delivery vehicle to obtain a 1 mgl/ml I-BET151 injection solution.</p></list-item></list></list-item><list-item><p>d. Sub aliquot into fresh glass vials for use during the duration of the study.</p><list list-type="simple"><list-item><p>i. Make 21 aliquots for each injection solution (3 mg/ml, 2 mg/ml, and 1 mg/ml) at 1.8 ml/vial.</p></list-item><list-item><p>ii. Store at 4°C.</p><list list-type="simple"><list-item><p>1. Dose stability has been determined for 21 days following storage at +4°C. If study duration is longer than 21 days another dose would need to be prepared on day 22.</p></list-item></list></list-item></list></list-item><list-item><p>e. Bring one aliquot of each injection solution (3 mg/ml, 2 mg/ml, and 1 mg/ml) to room temperature before injection.</p></list-item></list></list-item><list-item><p>Continue dosing mice with either drug or vehicle every day for 21 days.</p><list list-type="simple"><list-item><p>a. Monitor mice daily for signs of disease (activity, posture, fur texture, and mobility).</p></list-item><list-item><p>b. Weigh mice once a week.</p></list-item><list-item><p>c. Record scores according to the ‘Mouse Health Scoring System’ (see step 4a).</p></list-item><list-item><p>d. Euthanize mice when they receive a heath monitoring score of 3. This includes early signs of loss of hind limb motility, which is indicative of this disease model (<xref ref-type="bibr" rid="bib21">O'Farrell et al., 2003</xref>; <xref ref-type="bibr" rid="bib15">Lopes de Menezes et al., 2005</xref>).</p></list-item><list-item><p>e. Euthanize all remaining mice within 3 days of the last treatment.</p></list-item></list></list-item><list-item><p>The MTD will be determined by identifying the dose at which the group body weight loss does not exceed 20% compared with the vehicle group and at which morbidity is not observed in one or more animals. When the MTD is reached, the next lowest dose will be used in Protocol 5.</p></list-item></list></p></sec></sec><sec id="s2-4-4"><title>Deliverables</title><p><list list-type="simple"><list-item><p>■ Data to be collected:</p><list list-type="simple"><list-item><p>○ STR profile and result of mycoplasma and pathogen testing of cells.</p></list-item><list-item><p>○ Mouse health records (health monitoring [scores 0–3], weekly animal weights, date of treatment, euthanasia, and cause of termination).</p></list-item><list-item><p>○ Kaplan–Meier survival curves by group.</p></list-item><list-item><p>○ All flow cytometry plots in gating scheme (including controls), leading to final populations of HLA-A,B,C<sup>+</sup> cells before treatment intervention.</p></list-item></list></list-item></list></p></sec><sec id="s2-4-5"><title>Confirmatory analysis plan</title><p><list list-type="simple"><list-item><p>■ n/a.</p></list-item></list></p></sec><sec id="s2-4-6"><title>Known differences from the original study</title><p>The original study conditioned the recipient mice with a sublethal dose of radiation (300 cGy) prior to injection of MV4;11 cells. The replication attempt will use a single dose of busulfan, which has been reported to be comparable for human cell engraftment in NOD-SCID mice (<xref ref-type="bibr" rid="bib23">Robert-Richard et al., 2006</xref>). All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-4-7"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. Additionally, cells used for xenograft injection will be screened against a Rodent Pathogen Panel to ensure no contamination prior to injection. The animals will be randomized prior to treatment. All of the raw data will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/hcqqy">https://osf.io/hcqqy</ext-link>) and made publically available.</p></sec></sec><sec id="s2-5"><title>Protocol 5: Generation of disseminated xenograft AML mouse model and testing of I-BET151 compound in vivo</title><p>This protocol assesses the efficacy of I-BET151 as a therapeutic agent in a xenograft mouse model of leukemia. Immunocompromised mice will be injected with preparations of MV4;11 cells and disease will progress for 21 days. At day 21, mice will be treated either with I-BET151 or vehicle control. Disease-free progression will be measured and plotted, as reported in Figure 4B. The presence and degree of disease progression will be determined by measuring the number of human leukemia cells present in the PB, spleen, and bone marrow (BM) of leukemic xenograft mice. Leukemic mice treated with I-BET151 will be compared to mice treated with vehicle control. This protocol replicates the experiments reported in Figure 4D and Supp. Figure 16A.</p><sec id="s2-5-1"><title>Sampling</title><p><list list-type="simple"><list-item><p>■ Experiment has two cohorts:</p><list list-type="simple"><list-item><p>○ NOD/SCID mice treated daily with vehicle only.</p></list-item><list-item><p>○ NOD/SCID mice treated daily with dose of I-BET151 determined in Protocol 4.</p></list-item></list></list-item><list-item><p>■ Experiment will use 14 mice per treatment group.</p><list list-type="simple"><list-item><p>○ To account for a higher censor rate, or exclusion, 14 mice will be used per group to ensure enough mice are included to reach a minimum power of 80%.</p><list list-type="simple"><list-item><p>○ See ‘Power calculations’ section for details.</p></list-item></list></list-item></list></list-item></list></p></sec><sec id="s2-5-2"><title>Materials and reagents</title><p><table-wrap id="tblu5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>MV4;11</td><td>Human cell line</td><td>ATCC</td><td>CRL-9591</td><td>–</td></tr><tr><td>I-BET151 (GSK1210151A)</td><td>Small molecule</td><td>Sigma–Aldrich</td><td>SML0666</td><td>–</td></tr><tr><td>DMSO, molecular biology grade</td><td>Reagent</td><td>Sigma–Aldrich</td><td>D1435</td><td>Original brand not specified</td></tr><tr><td>RPMI-1640 medium, with L-glutamine and sodium bicarbonate</td><td>Cell culture reagent</td><td>Gibco, Life Technologies</td><td>22400-089</td><td>Original catalog number not specified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture reagent</td><td>Sigma–Aldrich</td><td>F2442</td><td>Original brand not specified</td></tr><tr><td>Penicillin–streptomycin solution (100×) stabilized</td><td>Cell culture reagent</td><td>Invitrogen</td><td>15140122</td><td>Original brand not specified</td></tr><tr><td>Phosphate buffered saline (PBS)</td><td>Buffer</td><td>Gibco, Life Technologies</td><td>14190-136</td><td>–</td></tr><tr><td>Female and male NOD-SCID mice (6–8 weeks old)</td><td>Animal model</td><td>Jackson Laboratory</td><td>001303</td><td>–</td></tr><tr><td>IV Busulfex (busulfan)</td><td>Chemical</td><td>Otsuka America Pharmaceutical, Inc.</td><td>NDC 59148-070-90</td><td>Not originally used</td></tr><tr><td>Ammonium chloride solution</td><td>Chemical</td><td>Stem Cell Technologies</td><td>07850</td><td>Replaces red blood cell lysis buffer from 5 prime</td></tr><tr><td>CountBright absolute counting beads</td><td>Flow cytometry reagent</td><td>Life Technology</td><td>C36950</td><td>Not originally used</td></tr><tr><td>FACS lysing solution</td><td>Chemical</td><td>Becton–Dickinson</td><td>349202</td><td>Replaces red blood cell lysis buffer from 5 prime</td></tr><tr><td>½ cc LO-DOSE U-100 insulin syringe 28G</td><td>Labware</td><td>Becton–Dickinson</td><td>329461</td><td>Original brand not specified</td></tr><tr><td>APC anti-human HLA-A,B,C antibody</td><td>Antibodies</td><td>Biolegend</td><td>311410</td><td>Original catalog number not specified</td></tr><tr><td>APC mouse IgG2a, κ isotype control antibody</td><td>Antibodies</td><td>Biolegend</td><td>400220</td><td>–</td></tr><tr><td>Annexin V-FITC Kit</td><td>Antibodies</td><td>Miltenyi Biotec Ltd</td><td>130-092-052</td><td>Original catalog number not specified</td></tr><tr><td>7-AAD</td><td>Dye</td><td>BD Pharmingen</td><td>51-68981E</td><td>Original catalog number not specified</td></tr><tr><td>Kleptose HPB</td><td>Chemical</td><td>Roquette Pharma</td><td>n/a</td><td>Original brand not specified</td></tr><tr><td>0.9% NaCl, USP</td><td>Chemical</td><td>Hospira, Inc</td><td>0490-1966-05</td><td>Original brand not specified</td></tr><tr><td>1cc insulin syringe U-100 27G 5/8</td><td>Labware</td><td>Becton–Dickinson</td><td>329412</td><td>Original brand not specified</td></tr><tr><td>Flow cytometer</td><td>Instrument</td><td>Becton–Dickinson</td><td>n/a</td><td>Canto or LSR II (replaces CyAn ADP from Dako)</td></tr><tr><td>FlowJo software</td><td>Software</td><td>Tree Star, Inc</td><td>n/a</td><td>–</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-5-3"><title>Procedure</title><sec id="s2-5-3-1"><title>Note</title><p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling, as well as screened against a Rodent Pathogen Panel.</p></list-item><list-item><p>MV4;11 human leukemic cells maintained in RPMI-1640 medium, supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C with 5% CO<sub>2</sub>.</p></list-item></list><list list-type="order"><list-item><p>Receive female and male NOD-SCID mice (6–8 weeks old).</p><list list-type="simple"><list-item><p>a. An equal number of male and female mice should be used.</p></list-item><list-item><p>b. Allow animals 1 week to acclimatize in a pathogen-free enclosure before start of study.</p></list-item><list-item><p>c. Animals are housed in sterile conditions using HEPA-filtered micro-isolator with 12-hr light/dark cycles, and fed with sterile rodent chow and acidified water ad libitum.</p></list-item></list></list-item><list-item><p>Condition mice with 30 mg/kg busulfan by intraperitoneal injection 24 hr prior to injection of MV4;11 cells.</p></list-item><list-item><p>Intravenously inject 1 × 10<sup>7</sup> MV4;11 cells in 0.2 ml sterile vehicle (PBS) into the tail vein of conditioned mice.</p></list-item><list-item><p>Monitor mice for engraftment as described in step 4 of Protocol 4.</p></list-item><list-item><p>Randomize mice into four cohorts using the following method.</p><list list-type="simple"><list-item><p>a. Exclude mice with no detectable leukemia burden.</p><list list-type="simple"><list-item><p>i. Use 0.5% human leukemia cells (HLA-A,B,C<sup>+</sup> cells) over the total live nucleated cells (human and mouse cells) in sample as a minimum threshold of engraftment (leukemia detected).</p></list-item></list></list-item><list-item><p>b. Animals are randomized according to a stratified randomization procedure to balance gender and baseline tumor characteristics.</p><list list-type="simple"><list-item><p>i. Female and male mice are assigned into separate blocks.</p></list-item><list-item><p>ii. In each block, animals are ranked according to disease burden (percent human HLA-A,B,C<sup>+</sup> cells) and group assignment is performed with a simple randomization procedure.</p></list-item></list></list-item></list></list-item><list-item><p>Begin once daily intraperitoneal injections with vehicle control or I-BET151 dose determined from Protocol 4 (dose volume is 10 ml/kg).</p><list list-type="simple"><list-item><p>a. Prepare vehicle and drug as outlined in step 6 of Protocol 4.</p></list-item><list-item><p>b. The same lot of I-BET151 will be used.</p></list-item></list></list-item><list-item><p>Continue dosing mice with either drug or vehicle every day for 21 days.</p><list list-type="simple"><list-item><p>a. Monitor mice as described in step 7 of Protocol 4.</p></list-item><list-item><p>b. Euthanize mice when they receive a health-monitoring score of 3 or within 3 days of the last treatment.</p></list-item></list></list-item><list-item><p>At sacrifice, collect PB by cardiac puncture into EDTA-treated tubes. Remove spleen and both tibias and femurs per mouse.</p><list list-type="simple"><list-item><p>a. Prepare cell suspensions from spleen (SPL) by pressing the spleen through a cell strainer in PBS and BM cells by flushing both tibias and femurs with PBS following the replicating lab's standard protocols.</p></list-item><list-item><p>b. For HLA-A,B,C and apoptosis analysis (step 9 below), lyse red blood cells from samples using ammonium chloride solution following manufacturer's instructions.</p></list-item><list-item><p>c. Collect two equal aliquots of cells for HLA-A,B,C and apoptosis analysis (step 9 below) and leukemia burden (step 10 below).</p></list-item></list></list-item><list-item><p>Perform flow cytometric analysis for apoptosis analysis in PB, SPL, and BM cells using Annexin V-FITC kit.</p><list list-type="simple"><list-item><p>a. Stain no more than 1 × 10<sup>6</sup> cells per sample with the following antibodies according to manufacturer's recommendations in PBS supplemented with 0.1% bovine serum albumin and 1 mM EDTA.</p><list list-type="simple"><list-item><p>i. APC conjugated anti-human HLA-A,B,C with 7-AAD and Annexin V-FITC.</p></list-item><list-item><p>ii. APC conjugated isotype control with 7-AAD and Annexin V-FITC.</p></list-item></list></list-item><list-item><p>b. Gating strategy:</p><list list-type="simple"><list-item><p>i. On FSC vs HLA-A,B,C plot, gate on HLA-A,B,C<sup>+</sup> cells (human leukemia cells).</p></list-item><list-item><p>ii. From the leukemia cell population, use Annexin V vs 7-AAD plot to gate on the following cell populations:</p><list list-type="simple"><list-item><p>1. Annexin<sup>+</sup> 7-AAD<sup>−</sup> population (apoptotic cells).</p></list-item><list-item><p>2. Annexin<sup>+</sup> 7-AAD<sup>+</sup> population (dead cells).</p></list-item></list></list-item></list></list-item></list></list-item><list-item><p>Perform flow cytometry analysis for leukemia burden in PB, SPL, and BM cells.</p><list list-type="simple"><list-item><p>a. Stain PB, SPL, and BM cells in a sample volume of 50 µl each. Add 20 µl of the following antibodies and incubate at room temperature for 15 min.</p><list list-type="simple"><list-item><p>i. APC conjugated anti-human HLA-A,B,C.</p></list-item><list-item><p>ii. APC conjugated isotype control.</p></list-item></list></list-item><list-item><p>b. Add CountBright absolute counting beads in 1× FACS lysing solution and incubate at room temperature for 15 min.</p></list-item><list-item><p>c. Perform flow cytometric analysis following manufacturer's instructions.</p></list-item><list-item><p>d. Gating strategy:</p><list list-type="simple"><list-item><p>i. On the FL3-H vs FSC plot, gate on CountBright absolute counting beads.</p></list-item><list-item><p>ii. On SSC vs FSC plot, gate on total nucleated population (both mouse and human cells).</p></list-item><list-item><p>iii. From the nucleated population, use HLA-A,B,C vs SSC plot to gate on HLA-A,B,C<sup>+</sup> cells (human leukemia cells).</p></list-item></list></list-item></list></list-item><list-item><p>For each mouse, confirm the presence or absence of leukemia. If a mouse is euthanized before the end of the experiment time length, but does not have detectable disease as assessed by flow cytometry, they should be censored from the Kaplan–Meier survival curve.</p><list list-type="simple"><list-item><p>a. Use 0.5% human leukemia cells (HLA-A,B,C<sup>+</sup> cells) over the total live nucleated cells (human and mouse cells) in sample as a minimum threshold of engraftment (leukemia detected).</p></list-item></list></list-item></list></p></sec></sec><sec id="s2-5-4"><title>Deliverables</title><p><list list-type="simple"><list-item><p>■ Data to be collected:</p><list list-type="simple"><list-item><p>○ STR profile and result of mycoplasma and pathogen testing of cells.</p></list-item><list-item><p>○ Mouse health records (health monitoring (scores 0–3), weekly animal weights, date of treatment, euthanasia, and cause of termination).</p></list-item><list-item><p>○ Kaplan–Meier survival curve comparing disease-free survival of I-BET151-treated xenografted mice vs vehicle-treated control xenografted mice. Compare to Figure 4B.</p></list-item><list-item><p>○ Include raw disease-free survival data for I-BET151 treated and untreated xenografted mice, including any mice censored because of no detectable disease.</p></list-item><list-item><p>○ All flow cytometry plots in gating scheme (including controls), leading to final populations of HLA-A,B,C<sup>+</sup> cells before and after treatment intervention. Compare to Figure 4D and Supplemental Figure S16A.</p></list-item><list-item><p>○ Number of HLA-A,B,C<sup>+</sup> cells in PB, SPL, and BM in each treatment group.</p></list-item></list></list-item></list></p></sec><sec id="s2-5-5"><title>Confirmatory analysis plan</title><p><list list-type="simple"><list-item><p>■ Statistical analysis of the replication data:</p><list list-type="simple"><list-item><p>○ Comparison of Kaplan–Meier survival curves between vehicle and I-BET151-treated mice using the Log-rank Mantel–Cox test.</p></list-item></list></list-item><list-item><p>■ Meta-analysis of effect sizes:</p><list list-type="simple"><list-item><p>○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper, and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></list-item></list></p></sec><sec id="s2-5-6"><title>Known differences from the original study</title><p>The original study conditioned the recipient mice with a sublethal dose of radiation (300 cGy) prior to injection of MV4;11 cells. The replication attempt will use a single dose of busulfan, which has been reported to be comparable for human cell engraftment in NOD-SCID mice (<xref ref-type="bibr" rid="bib23">Robert-Richard et al., 2006</xref>). The original study counted PB cells using a SciVet abc machine, while the replication attempt will include CountBright absolute counting beads to determine the absolute number of human leukemia cells in each mouse after treatment. The original study lysed red blood cells from samples using Red Blood Cell Lysis Buffer, while the replication attempt will use ammonium chloride solution while performing HLA-A,B,C and 7-AAD analysis. For analysis of leukemia burden using CountBright absolute counting beads, the cells will be lysed using 1× DB Lysis Buffer during manufacturer's instructions. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-5-7"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Additionally, cells used for xenograft injection will be screened against a Rodent Pathogen Panel to ensure no contamination prior to injection. The animals will be randomized prior to treatment. The apoptotic marker dye 7-AAD will be used to exclude populations of dead or dying cells from analysis and an isotype control antibody will be used to confirm the specificity of the HLA-A,B,C antibody. All of the raw data will be uploaded to the project page on the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/hcqqy">https://osf.io/hcqqy</ext-link>) and made publically available.</p></sec></sec></sec><sec id="s3"><title>Power calculations</title><p>For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:</p><p><ext-link ext-link-type="uri" xlink:href="https://osf.io/bdk6c/">https://osf.io/bdk6c/</ext-link>.</p><sec id="s3-1"><title>Protocol 1</title><p>Not applicable.</p></sec><sec id="s3-2"><title>Protocol 2</title><p>Summary of original data reported in Figures 2A, S11A, and S11B:<table-wrap id="tblu6" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Cell line</th><th>IC<sub>50</sub></th></tr></thead><tbody><tr><td>K562 cells (−MLL)</td><td>&gt;100 µM</td></tr><tr><td>MV4;11 cells (+MLL)</td><td>26 nM</td></tr></tbody></table></table-wrap></p><p>The original data do not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p><sec id="s3-2-1"><title>Test family</title><p><list list-type="simple"><list-item><p>■ Two-tailed <italic>t</italic>-test, difference between two independent mean values, alpha error = 0.05.</p></list-item></list></p><p>‘Power calculations’ performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).<table-wrap id="tblu7" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td colspan="6">2% variance</td></tr><tr><td>K562</td><td>MV4;11</td><td>70.69229</td><td>99.9%</td><td>2</td><td>2</td></tr><tr><td colspan="6">15% variance</td></tr><tr><td>K562</td><td>MV4;11</td><td>9.42564</td><td>98.8</td><td>2</td><td>2</td></tr><tr><td colspan="6">28% variance</td></tr><tr><td>K562</td><td>MV4;11</td><td>5.04945</td><td>99.4%</td><td>3</td><td>3</td></tr><tr><td colspan="6">40% variance</td></tr><tr><td>K562</td><td>MV4;11</td><td>3.53461</td><td>89.2%</td><td>3</td><td>3</td></tr></tbody></table></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment three times. Each time we will determine the IC<sub>50</sub>. The three replicates and the original reported value will be checked to see if the original value is an outlier using Grubb's test (with a significance level of 0.05). If the original value is detected as an outlier it will not be included with the replication replicates to determine the standard deviation of IC<sub>50</sub> values, otherwise it will be included in the standard deviation calculation. The calculated standard deviation will be combined with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></sec></sec><sec id="s3-3"><title>Protocol 3</title><p>Summary of original data estimated from graph reported in Figure 3D:<table-wrap id="tblu8" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Cell line</th><th>Treatment</th><th>Mean</th><th>Stdev</th><th>N</th></tr></thead><tbody><tr><td rowspan="2">K562 cells (−MLL)</td><td>DMSO</td><td>1</td><td>0</td><td>3</td></tr><tr><td>I-BET151</td><td>0.22</td><td>0.03</td><td>3</td></tr><tr><td rowspan="2">MV4;11 cells (+MLL)</td><td>DMSO</td><td>1</td><td>0</td><td>3</td></tr><tr><td>I-BET151</td><td>0.935</td><td>0.05</td><td>3</td></tr></tbody></table></table-wrap></p><sec id="s3-3-1"><title>Test family</title><p><list list-type="simple"><list-item><p>■ Two-tailed <italic>t</italic>-test, difference between two independent mean values, Bonferroni's correction: alpha error = 0.01667.</p></list-item></list></p><p>‘Power calculations’ performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).<table-wrap id="tblu9" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>MV4;11, I-BET151 treated</td><td>K562, I-BET151 treated</td><td>17.34130</td><td>99.3%<xref ref-type="table-fn" rid="tblfn1">*</xref></td><td>2<xref ref-type="table-fn" rid="tblfn1">*</xref></td><td>2<xref ref-type="table-fn" rid="tblfn1">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>*</label><p>Three samples per group will be used based on the other planned tests making the power 99.9%.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3-3-2"><title>Test family</title><p><list list-type="simple"><list-item><p>■ Two-tailed <italic>t</italic>-test, difference from constant (one sample case), Bonferroni's correction: alpha error = 0.01667.</p></list-item></list></p><p>‘Power calculations’ performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).<table-wrap id="tblu10" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>MV4;11, DMSO treated</td><td>MV4;11, I-BET151 treated</td><td>26.000</td><td>99.9%</td><td>3</td><td>3</td></tr></tbody></table></table-wrap></p></sec><sec id="s3-3-3"><title>Test family</title><p><list list-type="simple"><list-item><p>■ Two-tailed <italic>t</italic>-test, difference from constant (one sample case), Bonferroni's correction: alpha error = 0.01667.</p></list-item></list></p><p>Sensitivity calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).<table-wrap id="tblu11" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Detectable effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>K562, DMSO treated</td><td>K562, I-BET151 treated</td><td>5.66748<xref ref-type="table-fn" rid="tblfn2">*</xref></td><td>80.0%</td><td>3<xref ref-type="table-fn" rid="tblfn2">*</xref></td><td>3<xref ref-type="table-fn" rid="tblfn2">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><label>*</label><p>Since the original comparison was not statistically significant. This is the effect size that can be detected with 80% power and the indicated sample size. Unlike the above power calculations, the aim of this sensitivity calculation is not to detect the original effect size, but to understand what effect size could be detected. The original effect size is 1.300.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s3-4"><title>Protocol 4</title><p>The law of diminishing return was used to determine the sample size for assessment of MTD (<xref ref-type="bibr" rid="bib2">Charan and Kantharia, 2013</xref>).<list list-type="simple"><list-item><p>■ E = Total number of animals − Total number of groups.</p></list-item></list><table-wrap id="tblu12" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Number of treatment groups</th><th>Total sample size with E = 10</th><th>Total sample size with E = 20</th></tr></thead><tbody><tr><td>4</td><td>14<xref ref-type="table-fn" rid="tblfn3">*</xref></td><td>24<xref ref-type="table-fn" rid="tblfn3">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><label>*</label><p>To keep animals per group balanced 16 (4 per group), 20 (5 per group), or 24 (6 per group) total samples keeps E between 10 and 20. 20 total animals (5 per group) will be used to account for any potential exclusion.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3-5"><title>Protocol 5</title><p>Summary of original data estimated from Kaplan–Meier graph reported in Figure 4B:<table-wrap id="tblu13" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Treatment group</th><th>Median survival</th><th>Hazard ratio (to vehicle control)</th><th>N</th><th>Censoring rate (# censored/day)</th></tr></thead><tbody><tr><td>Vehicle-treated mice</td><td>14 days</td><td>N/A</td><td>5</td><td>0</td></tr><tr><td>I-BET151-treated mice</td><td>N/A</td><td>0.09687</td><td>5</td><td>0.09524<xref ref-type="table-fn" rid="tblfn4">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><label>*</label><p>Two mice were censored from the I-BET151 cohort during the 21-day treatment period. For the power calculations, the censoring rate was divided in half since the calculation assumes the censoring rate is equal for both groups.</p></fn></table-wrap-foot></table-wrap></p><sec id="s3-5-1"><title>Test family</title><p><list list-type="simple"><list-item><p>■ Log-rank (Mantel–Cox) test: alpha error = 0.05.</p></list-item></list></p><p>‘Power calculations’ performed with the <ext-link ext-link-type="uri" xlink:href="http://www.sample-size.net/sample-size-survival-analysis/">Sample Size Calculator</ext-link> hosted by the UCSF Clinical and Translational Science Institute (<xref ref-type="bibr" rid="bib24">Schoenfeld, 1983</xref>).<table-wrap id="tblu14" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Treatment duration</th><th>A priori power</th><th>Group 1 total events needed</th><th>Group 1 sample size</th><th>Group 2 total events needed</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>Vehicle</td><td>I-BET151</td><td>21 days</td><td>80.0%</td><td>5<xref ref-type="table-fn" rid="tblfn5">*</xref></td><td>12<xref ref-type="table-fn" rid="tblfn5">*</xref></td><td>1<xref ref-type="table-fn" rid="tblfn5">*</xref></td><td>12<xref ref-type="table-fn" rid="tblfn5">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><label>*</label><p>14 per group will be used to account for a potential higher censoring rate, or exclusion.</p></fn></table-wrap-foot></table-wrap></p></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The Reproducibility Project: Cancer Biology core team would like to thank the original authors, in particular Mark Dawson for generously sharing critical information to ensure the fidelity and quality of this replication attempt. We thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type Culture Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma–Aldrich, and System Biosciences (SBI).</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>JJF: ProNovus Bioscience is a Science Exchange associated laboratory.</p></fn><fn fn-type="conflict" id="conf2"><p>AK: ProNovus Bioscience is a Science Exchange associated laboratory.</p></fn><fn fn-type="conflict" id="conf3"><p>XS: Stem Cell and Xenograft Core, University of Pennsylvania Perelman School of Medicine is a Science Exchange associated laboratory.</p></fn><fn fn-type="conflict" id="conf4"><p>GD-D: Stem Cell and Xenograft Core, University of Pennsylvania Perelman School of Medicine is a Science Exchange associated laboratory.</p></fn><fn fn-type="conflict" id="conf5"><p>RP:CB: EI, FT, JL, and NP: Employed by and hold shares in Science Exchange Inc.</p></fn><fn fn-type="conflict" id="conf6"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>JJF, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>AK, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>XS, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>GD-D, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>MG, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>KO, Drafting or revising the article</p></fn><fn fn-type="con" id="con7"><p>RP:CB, Conception and design, Drafting or revising the article</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.08997.002</object-id><label>Supplementary file 1.</label><caption><title>Mouse Health Scoring System.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.08997.002">http://dx.doi.org/10.7554/eLife.08997.002</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-08997-supp1-v1.xlsx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaidos</surname><given-names>A</given-names></name><name><surname>Caputo</surname><given-names>V</given-names></name><name><surname>Gouvedenou</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Marigo</surname><given-names>I</given-names></name><name><surname>Chaudhry</surname><given-names>MS</given-names></name><name><surname>Rotolo</surname><given-names>A</given-names></name><name><surname>Tough</surname><given-names>DF</given-names></name><name><surname>Smithers</surname><given-names>NN</given-names></name><name><surname>Bassil</surname><given-names>AK</given-names></name><name><surname>Chapman</surname><given-names>TD</given-names></name><name><surname>Harker</surname><given-names>NR</given-names></name><name><surname>Barbash</surname><given-names>O</given-names></name><name><surname>Tummino</surname><given-names>P</given-names></name><name><surname>Al-Mahdi</surname><given-names>N</given-names></name><name><surname>Haynes</surname><given-names>AC</given-names></name><name><surname>Cutler</surname><given-names>L</given-names></name><name><surname>Le</surname><given-names>B</given-names></name><name><surname>Rahemtulla</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>I</given-names></name><name><surname>Kleijnen</surname><given-names>M</given-names></name><name><surname>Witherington</surname><given-names>JJ</given-names></name><name><surname>Parr</surname><given-names>NJ</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Karadimitris</surname><given-names>A</given-names></name></person-group><year>2014</year><article-title>Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762</article-title><source>Blood</source><volume>123</volume><fpage>697</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-01-478420</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charan</surname><given-names>J</given-names></name><name><surname>Kantharia</surname><given-names>ND</given-names></name></person-group><year>2013</year><article-title>How to calculate sample size in animal studies?</article-title><source>Journal of Pharmacology &amp; Pharmacotherapeutics</source><volume>4</volume><fpage>303</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.4103/0976-500X.119726</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>KR</given-names></name><name><surname>Kobzik</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>TR</given-names></name><name><surname>Brewer</surname><given-names>J</given-names></name><name><surname>Delmonte</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Crawford</surname><given-names>JM</given-names></name><name><surname>Ferrara</surname><given-names>JL</given-names></name></person-group><year>1996</year><article-title>An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin</article-title><source>Blood</source><volume>88</volume><fpage>3230</fpage><lpage>3239</lpage></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cory</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>DC</given-names></name><name><surname>Adams</surname><given-names>JM</given-names></name></person-group><year>2003</year><article-title>The Bcl-2 family: roles in cell survival and oncogenesis</article-title><source>Oncogene</source><volume>22</volume><fpage>8590</fpage><lpage>8607</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207102</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><year>2002</year><article-title>Transcription factors as targets for cancer therapy</article-title><source>Nature Reviews. Cancer</source><volume>2</volume><fpage>740</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1038/nrc906</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Gudgin</surname><given-names>EJ</given-names></name><name><surname>Horton</surname><given-names>SJ</given-names></name><name><surname>Giotopoulos</surname><given-names>G</given-names></name><name><surname>Meduri</surname><given-names>E</given-names></name><name><surname>Robson</surname><given-names>S</given-names></name><name><surname>Cannizzaro</surname><given-names>E</given-names></name><name><surname>Osaki</surname><given-names>H</given-names></name><name><surname>Wiese</surname><given-names>M</given-names></name><name><surname>Putwain</surname><given-names>S</given-names></name><name><surname>Fong</surname><given-names>CY</given-names></name><name><surname>Grove</surname><given-names>C</given-names></name><name><surname>Craig</surname><given-names>J</given-names></name><name><surname>Dittmann</surname><given-names>A</given-names></name><name><surname>Lugo</surname><given-names>D</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Bullinger</surname><given-names>L</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name><name><surname>Vassiliou</surname><given-names>GS</given-names></name><name><surname>Huntly</surname><given-names>BJ</given-names></name></person-group><year>2014</year><article-title>Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia</article-title><source>Leukemia</source><volume>28</volume><fpage>311</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.338</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Dittmann</surname><given-names>A</given-names></name><name><surname>Giotopoulos</surname><given-names>G</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>WI</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Hopf</surname><given-names>C</given-names></name><name><surname>Savitski</surname><given-names>MM</given-names></name><name><surname>Huthmacher</surname><given-names>C</given-names></name><name><surname>Gudgin</surname><given-names>E</given-names></name><name><surname>Lugo</surname><given-names>D</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Chapman</surname><given-names>TD</given-names></name><name><surname>Roberts</surname><given-names>EJ</given-names></name><name><surname>Soden</surname><given-names>PE</given-names></name><name><surname>Auger</surname><given-names>KR</given-names></name><name><surname>Mirguet</surname><given-names>O</given-names></name><name><surname>Doehner</surname><given-names>K</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Huntly</surname><given-names>BJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year>2011</year><article-title>Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia</article-title><source>Nature</source><volume>478</volume><fpage>529</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/nature10509</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmore</surname><given-names>JE</given-names></name><name><surname>Issa</surname><given-names>GC</given-names></name><name><surname>Lemieux</surname><given-names>ME</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>HM</given-names></name><name><surname>Kastritis</surname><given-names>E</given-names></name><name><surname>Gilpatrick</surname><given-names>T</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Chesi</surname><given-names>M</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Ghobrial</surname><given-names>IM</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name></person-group><year>2011</year><article-title>BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title><source>Cell</source><volume>146</volume><fpage>904</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.017</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>A</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Karpova</surname><given-names>T</given-names></name><name><surname>McNally</surname><given-names>J</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name></person-group><year>2009</year><article-title>Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription</article-title><source>Molecular Biology of the Cell</source><volume>20</volume><fpage>4899</fpage><lpage>4909</lpage><pub-id pub-id-type="doi">10.1091/mbc.E09-05-0380</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Gunn</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>FE</given-names></name><name><surname>Lomax</surname><given-names>J</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year>2014</year><article-title>An open investigation of the reproducibility of cancer biology research</article-title><source>eLife</source><volume>3</volume><fpage>e04333</fpage><pub-id pub-id-type="doi">10.7554/eLife.04333</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>AG</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior Research Methods</source><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>SJ</given-names></name><name><surname>Mijatov</surname><given-names>B</given-names></name><name><surname>Gunatilake</surname><given-names>D</given-names></name><name><surname>Tiffen</surname><given-names>JC</given-names></name><name><surname>Gowrishankar</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Pupo</surname><given-names>GM</given-names></name><name><surname>Cullinane</surname><given-names>C</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Smithers</surname><given-names>N</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Rizos</surname><given-names>H</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name></person-group><year>2014</year><article-title>The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells</article-title><source>The Journal of Investigative Dermatology</source><volume>134</volume><fpage>2795</fpage><lpage>2805</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.243</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeRoy</surname><given-names>G</given-names></name><name><surname>Rickards</surname><given-names>B</given-names></name><name><surname>Flint</surname><given-names>SJ</given-names></name></person-group><year>2008</year><article-title>The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription</article-title><source>Molecular Cell</source><volume>30</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.01.018</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Rodriguez-Blanco</surname><given-names>J</given-names></name><name><surname>Pastori</surname><given-names>C</given-names></name><name><surname>Volmar</surname><given-names>CH</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name><name><surname>Capobianco</surname><given-names>A</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Pei</surname><given-names>XH</given-names></name><name><surname>Ayad</surname><given-names>NG</given-names></name><name><surname>Robbins</surname><given-names>DJ</given-names></name></person-group><year>2014</year><article-title>The BET bromodomain inhibitor i-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>35494</fpage><lpage>35502</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.595348</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes de Menezes</surname><given-names>DE</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Garrett</surname><given-names>EN</given-names></name><name><surname>Louie</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Wiesmann</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Shephard</surname><given-names>L</given-names></name><name><surname>Goldbeck</surname><given-names>C</given-names></name><name><surname>Oei</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Aukerman</surname><given-names>SL</given-names></name><name><surname>Heise</surname><given-names>C</given-names></name></person-group><year>2005</year><article-title>CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia</article-title><source>Clinical Cancer Research</source><volume>11</volume><fpage>5281</fpage><lpage>5291</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0358</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marschalek</surname><given-names>R</given-names></name></person-group><year>2010</year><article-title>Mixed lineage leukemia: roles in human malignancies and potential therapy</article-title><source>The FEBS Journal</source><volume>277</volume><fpage>1822</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07608.x</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>JA</given-names></name><name><surname>Conery</surname><given-names>AR</given-names></name><name><surname>Bryant</surname><given-names>BM</given-names></name><name><surname>Sandy</surname><given-names>P</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Mele</surname><given-names>DA</given-names></name><name><surname>Bergeron</surname><given-names>L</given-names></name><name><surname>Sims</surname><given-names>RJ</given-names><suffix>III</suffix></name></person-group><year>2011</year><article-title>Targeting MYC dependence in cancer by inhibiting BET bromodomains</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>108</volume><fpage>16669</fpage><lpage>16674</lpage><pub-id pub-id-type="doi">10.1073/pnas.1108190108</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kowarz</surname><given-names>E</given-names></name><name><surname>Hofmann</surname><given-names>J</given-names></name><name><surname>Renneville</surname><given-names>A</given-names></name><name><surname>Zuna</surname><given-names>J</given-names></name><name><surname>Trka</surname><given-names>J</given-names></name><name><surname>Ben Abdelali</surname><given-names>R</given-names></name><name><surname>Macintyre</surname><given-names>E</given-names></name><name><surname>De Braekeleer</surname><given-names>E</given-names></name><name><surname>De Braekeleer</surname><given-names>M</given-names></name><name><surname>Delabesse</surname><given-names>E</given-names></name><name><surname>de Oliveira</surname><given-names>MP</given-names></name><name><surname>Cave</surname><given-names>H</given-names></name><name><surname>Clappier</surname><given-names>E</given-names></name><name><surname>van Dongen</surname><given-names>JJ</given-names></name><name><surname>Balgobind</surname><given-names>BV</given-names></name><name><surname>van den Heuvel-Eibrink</surname><given-names>MM</given-names></name><name><surname>Beverloo</surname><given-names>HB</given-names></name><name><surname>Panzer-Grumayer</surname><given-names>R</given-names></name><name><surname>Teigler-Schlegel</surname><given-names>A</given-names></name><name><surname>Harbott</surname><given-names>J</given-names></name><name><surname>Kjeldsen</surname><given-names>E</given-names></name><name><surname>Schnittger</surname><given-names>S</given-names></name><name><surname>Koehl</surname><given-names>U</given-names></name><name><surname>Gruhn</surname><given-names>B</given-names></name><name><surname>Heidenreich</surname><given-names>O</given-names></name><name><surname>Chan</surname><given-names>LC</given-names></name><name><surname>Yip</surname><given-names>SF</given-names></name><name><surname>Krzywinski</surname><given-names>M</given-names></name><name><surname>Eckert</surname><given-names>C</given-names></name><name><surname>Moricke</surname><given-names>A</given-names></name><name><surname>Schrappe</surname><given-names>M</given-names></name><name><surname>Alonso</surname><given-names>CN</given-names></name><name><surname>Schafer</surname><given-names>BW</given-names></name><name><surname>Krauter</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>DA</given-names></name><name><surname>Zur Stadt</surname><given-names>U</given-names></name><name><surname>Te Kronnie</surname><given-names>G</given-names></name><name><surname>Sutton</surname><given-names>R</given-names></name><name><surname>Izraeli</surname><given-names>S</given-names></name><name><surname>Trakhtenbrot</surname><given-names>L</given-names></name><name><surname>Lo Nigro</surname><given-names>L</given-names></name><name><surname>Tsaur</surname><given-names>G</given-names></name><name><surname>Fechina</surname><given-names>L</given-names></name><name><surname>Szczepanski</surname><given-names>T</given-names></name><name><surname>Strehl</surname><given-names>S</given-names></name><name><surname>Ilencikova</surname><given-names>D</given-names></name><name><surname>Molkentin</surname><given-names>M</given-names></name><name><surname>Burmeister</surname><given-names>T</given-names></name><name><surname>Dingermann</surname><given-names>T</given-names></name><name><surname>Klingebiel</surname><given-names>T</given-names></name><name><surname>Marschalek</surname><given-names>R</given-names></name></person-group><year>2009</year><article-title>New insights to the MLL recombinome of acute leukemias</article-title><source>Leukemia</source><volume>23</volume><fpage>1490</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1038/leu.2009.33</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>D</given-names></name><name><surname>Garcia-Cuellar</surname><given-names>MP</given-names></name><name><surname>Bach</surname><given-names>C</given-names></name><name><surname>Buhl</surname><given-names>S</given-names></name><name><surname>Maethner</surname><given-names>E</given-names></name><name><surname>Slany</surname><given-names>RK</given-names></name></person-group><year>2009</year><article-title>Misguided transcriptional elongation causes mixed lineage leukemia</article-title><source>PLOS Biology</source><volume>7</volume><fpage>e1000249</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000249</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicodeme</surname><given-names>E</given-names></name><name><surname>Jeffrey</surname><given-names>KL</given-names></name><name><surname>Schaefer</surname><given-names>U</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Dewell</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Chandwani</surname><given-names>R</given-names></name><name><surname>Marazzi</surname><given-names>I</given-names></name><name><surname>Wilson</surname><given-names>P</given-names></name><name><surname>Coste</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Kirilovsky</surname><given-names>J</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Lora</surname><given-names>JM</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Tarakhovsky</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Suppression of inflammation by a synthetic histone mimic</article-title><source>Nature</source><volume>468</volume><fpage>1119</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1038/nature09589</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Farrell</surname><given-names>AM</given-names></name><name><surname>Abrams</surname><given-names>TJ</given-names></name><name><surname>Yuen</surname><given-names>HA</given-names></name><name><surname>Ngai</surname><given-names>TJ</given-names></name><name><surname>Louie</surname><given-names>SG</given-names></name><name><surname>Yee</surname><given-names>KW</given-names></name><name><surname>Wong</surname><given-names>LM</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>LB</given-names></name><name><surname>Town</surname><given-names>A</given-names></name><name><surname>Smolich</surname><given-names>BD</given-names></name><name><surname>Manning</surname><given-names>WC</given-names></name><name><surname>Murray</surname><given-names>LJ</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Cherrington</surname><given-names>JM</given-names></name></person-group><year>2003</year><article-title>SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</article-title><source>Blood</source><volume>101</volume><fpage>3597</fpage><lpage>3605</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-07-2307</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastori</surname><given-names>C</given-names></name><name><surname>Daniel</surname><given-names>M</given-names></name><name><surname>Penas</surname><given-names>C</given-names></name><name><surname>Volmar</surname><given-names>CH</given-names></name><name><surname>Johnstone</surname><given-names>AL</given-names></name><name><surname>Brothers</surname><given-names>SP</given-names></name><name><surname>Graham</surname><given-names>RM</given-names></name><name><surname>Allen</surname><given-names>B</given-names></name><name><surname>Sarkaria</surname><given-names>JN</given-names></name><name><surname>Komotar</surname><given-names>RJ</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name><name><surname>Ayad</surname><given-names>NG</given-names></name></person-group><year>2014</year><article-title>BET bromodomain proteins are required for glioblastoma cell proliferation</article-title><source>Epigenetics</source><volume>9</volume><fpage>611</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.4161/epi.27906</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert-Richard</surname><given-names>E</given-names></name><name><surname>Ged</surname><given-names>C</given-names></name><name><surname>Ortet</surname><given-names>J</given-names></name><name><surname>Santarelli</surname><given-names>X</given-names></name><name><surname>Lamrissi-Garcia</surname><given-names>I</given-names></name><name><surname>de Verneuil</surname><given-names>H</given-names></name><name><surname>Mazurier</surname><given-names>F</given-names></name></person-group><year>2006</year><article-title>Human cell engraftment after busulfan or irradiation conditioning of NOD/SCID mice</article-title><source>Haematologica</source><volume>91</volume><fpage>1384</fpage></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>DA</given-names></name></person-group><year>1983</year><article-title>Sample-size formula for the proportional-hazards regression model</article-title><source>Biometrics</source><volume>39</volume><fpage>499</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.2307/2531021</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slany</surname><given-names>RK</given-names></name></person-group><year>2009</year><article-title>The molecular biology of mixed lineage leukemia</article-title><source>Haematologica</source><volume>94</volume><fpage>984</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.3324/haematol.2008.002436</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year>2011</year><article-title>The super elongation complex (SEC) and MLL in development and disease</article-title><source>Genes &amp; Development</source><volume>25</volume><fpage>661</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1101/gad.2015411</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamai</surname><given-names>H</given-names></name><name><surname>Inokuchi</surname><given-names>K</given-names></name></person-group><year>2010</year><article-title>11q23/MLL acute leukemia: update of clinical aspects</article-title><source>Journal of Clinical and Experimental Hematopathology</source><volume>50</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.3960/jslrt.50.91</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolani</surname><given-names>B</given-names></name><name><surname>Gopalakrishnan</surname><given-names>R</given-names></name><name><surname>Punj</surname><given-names>V</given-names></name><name><surname>Matta</surname><given-names>H</given-names></name><name><surname>Chaudhary</surname><given-names>PM</given-names></name></person-group><year>2014</year><article-title>Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors</article-title><source>Oncogene</source><volume>33</volume><fpage>2928</fpage><lpage>2937</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.242</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SY</given-names></name><name><surname>Chiang</surname><given-names>CM</given-names></name></person-group><year>2007</year><article-title>The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>13141</fpage><lpage>13145</lpage><pub-id pub-id-type="doi">10.1074/jbc.R700001200</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyspianska</surname><given-names>BS</given-names></name><name><surname>Bannister</surname><given-names>AJ</given-names></name><name><surname>Barbieri</surname><given-names>I</given-names></name><name><surname>Nangalia</surname><given-names>J</given-names></name><name><surname>Godfrey</surname><given-names>A</given-names></name><name><surname>Calero-Nieto</surname><given-names>FJ</given-names></name><name><surname>Robson</surname><given-names>S</given-names></name><name><surname>Rioja</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wiese</surname><given-names>M</given-names></name><name><surname>Cannizzaro</surname><given-names>E</given-names></name><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Huntly</surname><given-names>B</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Gottgens</surname><given-names>B</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year>2014</year><article-title>BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms</article-title><source>Leukemia</source><volume>28</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.234</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Rappaport</surname><given-names>AR</given-names></name><name><surname>Herrmann</surname><given-names>H</given-names></name><name><surname>Sison</surname><given-names>EA</given-names></name><name><surname>Magoon</surname><given-names>D</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Blatt</surname><given-names>K</given-names></name><name><surname>Wunderlich</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>MJ</given-names></name><name><surname>Johns</surname><given-names>C</given-names></name><name><surname>Chicas</surname><given-names>A</given-names></name><name><surname>Mulloy</surname><given-names>JC</given-names></name><name><surname>Kogan</surname><given-names>SC</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name></person-group><year>2011</year><article-title>RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia</article-title><source>Nature</source><volume>478</volume><fpage>524</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nature10334</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.08997.003</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Adelman</surname><given-names>Karen</given-names></name><role>Reviewing editor</role><aff><institution>National Institute of Environmental Health Sciences</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for submitting your work entitled “Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia” for peer review at <italic>eLife</italic>. Your submission has been favourably evaluated by Charles Sawyers (Senior Editor), a Reviewing Editor, and three reviewers.</p><p>The reviewers have discussed their reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The manuscript is designed to replicate the major findings of Dawson et al.,‘Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia’ (Nature, 2011).</p><p>There are 3 main experiments chosen for replication. (i) To replicate the sensitivity of MLL rearranged leukaemia cell lines to BET bromodomain inhibition (ii) To assess the downregulation of BCL2, a major target gene and (iii) To assess the efficacy of I-BET against a xenograft model of leukaemia.</p><p>Detailed protocols are provided for replicating each of these key experiments, with increased sample sizes above the original manuscript to ensure statistical significance of results.</p><p>Essential revisions:</p><p>1) In general, the authors summarize the literature adequately. This area of biomedical/cancer research has been very active and there have been many studies that have demonstrated pre-clinical efficacy for BET bromodomain inhibition in various malignancies. Nonetheless the authors should cite Zuber et al. (Nature, 2011); Delmore et al. (Cell, 2011) and Mertz et al. (PNAS, 2011) as these studies were published concurrently to the Dawson et al. study. In particular:</p><p>a) The efficacy of JQ1 (an independent BET inhibitor) in MV4-11 xenografts was shown in Figure 5D of this study: Mertz JA et al. (Proc Natl Acad Sci, 2011, Oct 4;108(40):16669-74).</p><p>b) The differential sensitivity of MV4-11 and K562 proliferation in vitro was demonstrated in Supplement Figure 6 of this study: Zuber J et al. (Nature, 2011, Aug 3;478(7370):524-8).</p><p>2) From a statistical perspective, the proposal looks very detailed and acknowledges managing some of the uncertainty in the study design. There is also clear discussion of the randomisation processes to be used. However, there are some aspects that necessitate some clarification.</p><p>a) Protocol 2 allows for the fact that the original report does not report any error for the average value reported. Was any attempt made to get this data from the original authors? Getting the original data for error would be preferable to generating replicates to get an estimate of the SD from 3 new biological replicates and the original report. If that is not possible then I think the 3 new biological replicates will be added to the original report to make a sample size of 4 to estimate the SD. Then this SD will be used to scale the original (singly reported) value as a scaled effect size and then a new sample size calculation will be performed to see how many more than 3 will be needed to achieve 80% power.</p><p>b) Protocol 3. Within this protocol there is a sample size calculation (sensitivity) to see what effect size could be detected with n=3. However, this comparison was not statistically significant in the original report. I think the aim of this part of the protocol should be reworded.</p><p>c) Protocol 4. Five mice per group will be used in the MTD analysis and this will be reported using Kaplan Meier plots. However, no sample size justification was made. What is the reasoning for using 5 per group?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.08997.004</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>1) In general, the authors summarize the literature adequately. This area of biomedical/cancer research has been very active and there have been many studies that have demonstrated pre-clinical efficacy for BET bromodomain inhibition in various malignancies. Nonetheless the authors should cite Zuber et al. (Nature, 2011); Delmore et al. (Cell, 2011) and Mertz et al. (PNAS, 2011) as these studies were published concurrently to the Dawson et al. study. In particular</italic>:</p><p><italic>a) The efficacy of JQ1 (an independent BET inhibitor) in MV4-11 xenografts was shown in Figure 5D of this study: Mertz JA et al. (Proc Natl Acad Sci, 2011, Oct 4;108(40):16669-74)</italic>.</p><p><italic>b) The differential sensitivity of MV4-11 and K562 proliferation in vitro was demonstrated in Supplement Figure 6 of this study: Zuber J et al. (Nature, 2011, Aug 3;478(7370):524-8)</italic>.</p><p>Thank you for bringing these to our attention. We have updated the manuscript to include these references.</p><p><italic>2) From a statistical perspective, the proposal looks very detailed and acknowledges managing some of the uncertainty in the study design. There is also clear discussion of the randomisation processes to be used. However, there are some aspects that necessitate some clarification</italic>.</p><p><italic>a) Protocol 2 allows for the fact that the original report does not report any error for the average value reported. Was any attempt made to get this data from the original authors? Getting the original data for error would be preferable to generating replicates to get an estimate of the SD from 3 new biological replicates and the original report. If that is not possible then I think the 3 new biological replicates will be added to the original report to make a sample size of 4 to estimate the SD. Then this SD will be used to scale the original (singly reported) value as a scaled effect size and then a new sample size calculation will be performed to see how many more than 3 will be needed to achieve 80% power</italic>.</p><p>We did reach out to the original authors about obtaining the originally reported data. Unfortunately, they were unable to provide the raw data for any of the included experiments. Thank you for the suggestion regarding the approach to used the replication variation and the original (singly reported) value to calculate the effect size to use in a new sample size calculation. The one potential issue that could potentially arise is if the replication data are significantly different than the original value, which would cause the SD to greatly increase. Thus, we propose to include the original value as long as it is not detected as an outlier using Grubb’s test. We have updated the manuscript to include this approach.</p><p><italic>b) Protocol 3. Within this protocol there is a sample size calculation (sensitivity) to see what effect size could be detected with n=3. However, this comparison was not statistically significant in the original report. I think the aim of this part of the protocol should be reworded</italic>.</p><p>Thank you for the suggestion. We have reworded this part to increase the clarity of the calculation.</p><p><italic>c) Protocol 4. Five mice per group will be used in the MTD analysis and this will be reported using Kaplan Meier plots. However, no sample size justification was made. What is the reasoning for using 5 per group</italic></p><p>We have included the justification in the revised manuscript. The MTD will be determined using body weight loss and morbidity, while also reporting overall survival using Kaplan Meier plots. Sample size was determined using the law of diminishing return (since the primary aim is to find any level of difference between groups), with 5 animals per group sufficient to keep E between 10 and 20, while also accounting for any potential loss due to exclusion.</p></body></sub-article></article>